Radiation or Observation Only in Endometrial Cancer Who Have Undergone Surgery
Endometrial Cancer
About this trial
This is an interventional treatment trial for Endometrial Cancer focused on measuring stage I endometrial carcinoma, stage II endometrial carcinoma, endometrial adenocarcinoma, endometrial adenosquamous cell carcinoma, endometrial papillary carcinoma, endometrial clear cell carcinoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma or adenosquamous cell carcinoma of the endometrium Intermediate-risk of recurrence after laparoscopically-assisted vaginal hysterectomy (with or without laparoscopic staging) or total abdominal hysterectomy and bilateral salpingo-oophorectomy Postoperative pathologic stage IA/IB (grade 3), stage IC (grade 1-3), or stage IIA (all grades) Patients with more than 50% myometrial invasion (grade 1 or 2) or less than 50% myometrial invasion (grade 3) but with positive peritoneal cytology also eligible Patients whose sole criterion for increased risk is positive peritoneal cytology are not eligible No pathologically involved lymph nodes if staging procedure performed Stage I papillary serous or clear cell endometrial cancer allowed PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-3 Life expectancy: At least 3 years Hematopoietic: WBC at least 2,000/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 10 g/dL Hepatic: Not specified Renal: Creatinine less than 2 times upper limit of normal No serious renal disease that would preclude radiotherapy Cardiovascular: No serious cardiovascular disease that would preclude radiotherapy Other: No history of inflammatory bowel disease such as ulcerative colitis No other malignancy within past 5 years except curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, colon cancer, or thyroid cancer No psychiatric or addictive disorder that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: No prior anticancer hormonal therapy No concurrent progestogens Radiotherapy: No prior pelvic irradiation No prior or other concurrent vaginal intracavitary radiotherapy Surgery: See Disease Characteristics Other: No prior anticancer therapy No other concurrent anticancer therapy
Sites / Locations
- St. Mary's - Duluth Clinic Cancer Center
- Royal Women's Hospital
- Tom Baker Cancer Centre - Calgary
- Cross Cancer Institute
- Fraser Valley Cancer Centre at British Columbia Cancer Agency
- British Columbia Cancer Agency - Vancouver Cancer Centre
- Doctor Leon Richard Oncology Centre
- Saint John Regional Hospital
- Newfoundland Cancer Treatment and Research Foundation
- Nova Scotia Cancer Centre at Queen Elizabeth II Health Sciences Centre
- Margaret and Charles Juravinski Cancer Centre
- Cancer Centre of Southeastern Ontario
- London Regional Cancer Program at London Health Sciences Centre
- Northeastern Ontario Regional Cancer Centre
- Regional Cancer Care at Thunder Bay Regional Health Sciences Centre
- Princess Margaret Hospital
- Humber River Regional Hospital - Weston
- Cancer Care Ontario - Windsor Regional Cancer Centre
- CHUS-Hopital Fleurimont
- Hopital Charles Lemoyne
- Centre Hospitalier de l'Universite de Montreal
- McGill Cancer Centre at McGill University
- Centre Hospitalier Universitaire de Quebec
- Allan Blair Cancer Centre at Pasqua Hospital
- Saskatoon Cancer Centre
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Observation
Radiation
Post-operative pelvic radiation therapy (45 Gy in 25 fractions over 5 weeks)